Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
Robin Foà, Sabina Chiaretti
Abstract
Until recently, Ph-positive ALL was very aggressive and difficult to treat. Current frontline therapy, based on tyrosine kinase inhibitors, glucocorticoids, and blinatumomab, has increased survival, with high-level clearance of measurable tumor cells.
Topics & Concepts
BlinatumomabLymphoblastic LeukemiaPhiladelphia chromosomeTyrosine kinaseCancer researchMedicineTyrosine-kinase inhibitorChromosomal translocationInternal medicineOncologyLeukemiaBiologyGeneticsGeneReceptorCancerAcute Lymphoblastic Leukemia researchCAR-T cell therapy researchChronic Myeloid Leukemia Treatments